Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Uveitis is inflammation of the uvea, which is the middle layer of the eye that consists of the iris, ciliary body and choroid. Based on the location where the inflammation occurs in the uvea, the condition can be classified as: anterior uveitis, intermediate uveitis, posterior uveitis, and diffuse uveitis.

The global uveitis treatment market is estimated to account for US$ 648.4 Mn in terms of value in 2020 and is expected to reach US$ 1,036.0 Mn by the end of 2027.

Global Uveitis Treatment Market: Drivers

High prevalence of uveitis is expected to propel growth of the global uveitis treatment over the forecast period. For instance, according to the study, ‘Epidemiology of uveitis in urban Australia’, published in April 2019 in the journal Clinical and Experimental Ophthalmology, the incidence of uveitis was 21.54 per 100 000 person?years. The period prevalence of the condition was 36.27 per 100 000 persons.

Moreover, high incidence of autoimmune disorders is also expected to aid in growth of the market. For instance, according to a study by National MS Society, published in February 2019, in the journal Neurology, in 2017, nearly 1 million adults were living with multiple sclerosis in the U.S.

Corticosteroids held dominant position in the global uveitis treatment market in 2019, accounting for 21.1% share in terms of value, followed by Monoclonal Antibodies and Antibiotics, respectively.

Figure 1. Global Uveitis Treatment Market Share (%), by Value, by Treatment Type, 2019

Uveitis Treatment  | Coherent Market Insights

Global Uveitis Treatment Market: Restraints

Limited studies on efficacy comparison of treating agents are expected to hinder growth of the market. Due to the presence of very few studies regarding the efficacy of the agents used for treating uveitis, there have been very limited first line drugs, which are introduced for the treatment. Under various forms of uveitis, varying behavior of the patients have been observed with varying diagnoses and success in the treatment.

Moreover, challenging manufacturing process is also expected to limit the market growth. Eye care product needs unique manufacturing process for making the product appropriately aligned with the GMP regulations for sterile products. Since the formulations are prone to get affected by the pathogens available in the environment, they are formulated under highly protected area.

request-sample

Uveitis Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 605.7 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.9% 2027 Value Projection: US$ 1,036.0 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Treatment Type: Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal, Analgesics.
  • By Disease Type: Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Pan uveitis.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores.
Companies covered:

Allergan, Inc., Novartis AG, Valeant Pharmaceuticals International, Inc., Galapagos, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Inc., AbbVie Inc., Tarsius Pharma, Eyegate Pharmaceuticals, Inc., Alimera Sciences Inc., and pSivida Corp.

Growth Drivers:
  • High prevalence of uveitis
  • Number of treatment options
Restraints & Challenges:
  • Limited studies on efficacy comparison of treating agents
  • Challenging manufacturing process

Global Uveitis Treatment Market: Opportunities 

Promising compounds in clinical trials are expected to offer lucrative growth opportunities for players in the global uveitis treatment over the forecast period. For instance, in June 2020, Tarsius Pharma, a clinical-stage biopharmaceutical company, completed patient enrollment in the company's Phase I/II trial of TRS01 in patients with active anterior non-infectious uveitis.

High incidence of rheumatoid arthritis is also expected to aid in growth of the market. For instance, according to the study, “Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017”, published in the journal Annals of the Rheumatic Diseases, in November 2019, the age-standardized point prevalence and annual incidence rates of rheumatoid arthritis were 246.6 and 14.9 in 2017, which increased by 7.4% and 8.2% from 1990, respectively.

The global uveitis treatment market was valued at US$ 605.7 Mn in 2019 and is forecast to reach a value of US$ 1,036.0 Mn by 2027 at a CAGR of 6.9% between 2020 and 2027.

Figure 2. Global Uveitis Treatment Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Uveitis Treatment  | Coherent Market Insights

Market Trends/Key Takeaways

The prevalence of anterior uveitis is high in Asia Pacific. For instance, according to the study, ‘Epidemiology of uveitis in urban Australia’, published in April 2019 in the journal Clinical and Experimental Ophthalmology, the distribution of prevalent uveitis cases was anterior (75%), intermediate (6%), posterior (15%) and panuveitis (4%).

The emergence of Covid-19 has halted several clinical trials. For instance, in March 2020, Belgium-based Galapagos announced that the company is pausing enrollment in some clinical trials that include its Phase II and Phase III trials of filgotinib in Crohn’s disease, psoriatic arthritis and uveitis.

Global Uveitis Treatment Market: Competitive Landscape

Major players operating in the global uveitis treatment market include, Allergan, Inc., Novartis AG, Valeant Pharmaceuticals International, Inc., Galapagos, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Inc., AbbVie Inc., Tarsius Pharma,  Eyegate Pharmaceuticals, Inc., Alimera Sciences Inc., and pSivida Corp.

Global Uveitis Treatment Market: Key Developments

Major players in the market are focused on R&D of new products to expand their product portfolio. For instance, in March 2020, EyePoint Pharmaceuticals, Inc. announced positive topline 36-month follow-up data from the second Phase 3 trial of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Major players in the market are also focused on approval and launch of new products to expand their product portfolio. For instance, in December 2019, Alimera Sciences, Inc. was granted marketing authorization for ILUVIEN for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye, in Belgium, The Netherlands, and Luxembourg.

Uveitis refers to inflammation caused in the uvea of the eye. A uvea is the middle layer of the eye that consists of three components namely iris, cilliary body, and the choroid. Uveitis is caused by various factors such as inflammatory diseases, injuries in the eye, microbial infections such as viral, bacterial, and fungal infection or exposure to certain toxic chemicals such as strong acids or pesticides. However, in many cases the cause of this condition remains unknown. It is also found to be effecting people belonging to the age group of 20–50 years. The condition is classified based on the location of inflammation in the uvea and is categorized in three types including anterior uveitis that causes inflammation in the iris and is the most commonly encountered type.

Restraints of the Global Uveitis Treatment Market

Major factors hampering the growth of the uveitis treatment market during the forecast period constitutes of limited studies on efficacy comparison of treating agents, and challenging manufacturing process.

Key features of the study:

  • This report provides in-depth analysis of the global uveitis treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global uveitis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Allergan, Inc., Novartis AG, Valeant Pharmaceuticals International, Inc., Galapagos, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Inc., AbbVie Inc., Tarsius Pharma, Eyegate Pharmaceuticals, Inc., Alimera Sciences Inc., and pSivida Corp.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global uveitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Uveitis Treatment Market, By Treatment Type:
    • Corticosteroids
    • Immunosuppressant
    • Monoclonal Antibodies
    • Cycloplegic Agents
    • Antibiotics
    • Antivirals
    • Antifungal
    • Analgesics
  • Global Uveitis Treatment Market, By Disease Type:
    • Anterior Uveitis
    • Posterior Uveitis
    • Intermediate Uveitis
    • Pan uveitis
  • Global Uveitis Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Drug Stores
  • Global Uveitis Treatment Market, By Geography:
    • North America
      • By Treatment Type
        • Corticosteroids
        • Immunosuppressant
        • Monoclonal Antibodies
        • Cycloplegic Agents
        • Antibiotics
        • Antivirals
        • Antifungal
        • Analgesics
      • By Disease Type
        • Anterior Uveitis
        • Posterior Uveitis
        • Intermediate Uveitis
        • Pan uveitis
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Drug Stores
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Treatment Type
        • Corticosteroids
        • Immunosuppressant
        • Monoclonal Antibodies
        • Cycloplegic Agents
        • Antibiotics
        • Antivirals
        • Antifungal
        • Analgesics
      • By Disease Type
        • Anterior Uveitis
        • Posterior Uveitis
        • Intermediate Uveitis
        • Pan uveitis
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Drug Stores
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment Type
        • Corticosteroids
        • Immunosuppressant
        • Monoclonal Antibodies
        • Cycloplegic Agents
        • Antibiotics
        • Antivirals
        • Antifungal
        • Analgesics
      • By Disease Type
        • Anterior Uveitis
        • Posterior Uveitis
        • Intermediate Uveitis
        • Pan uveitis
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Drug Stores
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Treatment Type
        • Corticosteroids
        • Immunosuppressant
        • Monoclonal Antibodies
        • Cycloplegic Agents
        • Antibiotics
        • Antivirals
        • Antifungal
        • Analgesics
      • By Disease Type
        • Anterior Uveitis
        • Posterior Uveitis
        • Intermediate Uveitis
        • Pan uveitis
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Drug Stores
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Treatment Type
        • Corticosteroids
        • Immunosuppressant
        • Monoclonal Antibodies
        • Cycloplegic Agents
        • Antibiotics
        • Antivirals
        • Antifungal
        • Analgesics
      • By Disease Type
        • Anterior Uveitis
        • Posterior Uveitis
        • Intermediate Uveitis
        • Pan uveitis
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Drug Stores
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment Type
        • Corticosteroids
        • Immunosuppressant
        • Monoclonal Antibodies
        • Cycloplegic Agents
        • Antibiotics
        • Antivirals
        • Antifungal
        • Analgesics
      • By Disease Type
        • Anterior Uveitis
        • Posterior Uveitis
        • Intermediate Uveitis
        • Pan uveitis
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Drug Stores
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Allergan, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Novartis AG
    • Valeant Pharmaceuticals International, Inc.
    • Galapagos
    • EyePoint Pharmaceuticals, Inc.
    • Clearside Biomedical, Inc.
    • AbbVie Inc.
    • Tarsius Pharma
    • Eyegate Pharmaceuticals, Inc.
    • Alimera Sciences Inc.
    • pSivida Corp.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment Type
      • Market Snippet, By Disease Type
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis
  4. Global Uveitis Treatment Market, By Treatment Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Immunosuppressant
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Monoclonal Antibodies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Cycloplegic Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Antibiotics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Antivirals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Antifungal
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Analgesics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Uveitis Treatment Market, By Disease Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Anterior Uveitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Posterior Uveitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Intermediate Uveitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Pan uveitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Uveitis Treatment Market, By Distribution Channel, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Drug Stores
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Uveitis Treatment Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • Allergan, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Valeant Pharmaceuticals International, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Galapagos
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • EyePoint Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Clearside Biomedical, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Tarsius Pharma
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eyegate Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Alimera Sciences Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • pSivida Corp.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 26 figures on “Uveitis Treatment Market – Global forecast to 2027.

Frequently Asked Questions

The global uveitis treatment market was valued at US$ 605.7 Mn in 2019 and is forecast to reach a value of US$ 1,036.0 Mn by 2027 at a CAGR of 6.9% between 2020 and 2027.
Major factor driving the growth of global uveitis treatment market during the forecast period include high prevalence of uveitis, and number of treatment options.
Major factors hampering the growth of the uveitis treatment market during the forecast period constitutes of limited studies on efficacy comparison of treating agents, and challenging manufacturing process.
Corticosteroids held dominant position in the global uveitis treatment market in 2019.
North America Uveitis Treatment market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Allergan, Inc., Novartis AG, Valeant Pharmaceuticals International, Inc., Galapagos, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Inc., AbbVie Inc., Tarsius Pharma, Eyegate Pharmaceuticals, Inc., Alimera Sciences Inc., and pSivida Corp.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner